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Abstract
The objective of this study was to review the characteristics and outcome of prosthetic joint infections (PJI) due to Enterococcus sp. collected
in 18 hospitals from six European countries. Patients with a PJI due to Enterococcus sp. diagnosed between January 1999 and July 2012 were
retrospectively reviewed. Relevant information about demographics, comorbidity, clinical characteristics, microbiological data, surgical
treatment and outcome was registered. Univariable and multivariable analyses were performed. A total of 203 patients met the inclusion
criteria. The mean (SD) was 70.4 (13.6) years. In 59 patients the infection was diagnosed within the ﬁrst 30 days (29.1%) from arthroplasty,
in 44 (21.7%) between 31 and 90 days, in 54 (26.6%) between 91 days and 2 years and in 43 (21%) after 2 years. Enterococcus faecalis was
isolated in 176 cases (89%). In 107 (54%) patients the infection was polymicrobial. Any comorbidity (OR 2.53, 95% CI 1.18–5.40, p 0.01), and
fever (OR 2.65, 95% CI 1.23–5.69, p 0.01) were independently associated with failure. The only factor associated with remission was
infections diagnosed later than 2 years (OR 0.25, 95% CI 0.09–0.71, p 0.009). In conclusion, prosthetic joint infections due to Enterococcus
sp. were diagnosed within the ﬁrst 2 years from arthroplasty in >70% of the patients, almost 50% had at least one comorbidity and
infections were frequently polymicrobial (54%). The global failure rate was 44% and patients with comorbidities, fever, and diagnosed within
the ﬁrst 2 years from arthroplasty had a poor prognosis.
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Introduction
Prosthetic joint infection (PJI) is a severe complication that
occurs in 0.5–3% of arthroplasties [1–3] and staphylococci are
the most frequently isolated microorganisms [4]. Coagu-
lase-negative staphylococci account for 30–41% and Staphylo-
coccus aureus for 12–39%. Gram-negative organisms are less
common than Gram-positive, causing around 10% of cases [5].
Among Gram-positive bacteria, Enterococcus sp. account for 3–
10% [6–8]; however, the isolation of enterococci has been
associated with a worse outcome [9,10] probably due to the
tolerance of enterococci to different classes of antibiotics. The
largest case series was published by El Helou et al. [11] where
they described 50 cases treated in one institution over
30 years; however, polymicrobial infections were excluded
from the analysis and recent data suggest that PJI are
frequently polymicrobial—probably due to improvements in
sampling and microbiological methods.
The objective of this study was to review the characteristics
and outcomes of monomicrobial or polymicrobial PJI due to
Enterococcus sp. diagnosed and treated in 18 hospitals from six
European countries.
Patients and Methods
Setting and patients
Patients with a PJI due to Enterococcus sp. diagnosed between
January 1999 and July 2012 from 18 hospitals in six European
countries (France, Germany, Hungary, Italy, Slovenia and
Spain) were retrospectively reviewed. Relevant information
about demographics (age and gender), comorbidity (having or
not having one of the following entities: coronary disease,
diabetes mellitus, malignancy, liver cirrhosis, chronic renal
failure or chronic obstructive pulmonary disease), site of
implant, type of implant (cemented or non-cemented), age of
prosthesis, clinical manifestations (fever and wound drainage),
leucocyte count and value of C-reactive protein at the
moment of admission for infection, surgical treatment
(debridement with retention of the prosthesis, one-step
exchange or two-step exchange), isolated microorganisms,
antibiotic treatment directed to enterococci, duration of the
total antibiotic therapy, and outcome were recorded. Diag-
nosis of PJI was based upon clinical symptoms and signs (such
as joint pain, redness, fever, wound drainage, presence of a
sinus tract or purulence, and other inﬂammatory signs) and
isolation of enterococci in at least two deep samples. PJI were
divided according to the age of implant at the moment of
infection diagnosis into ≤30, 31–90, 91 days to <2 years and
>2 years. Information was introduced in a database specially
designed for the study. Two co-authors (A.S. and E.T.)
reviewed all cases and contacted collaborating centres to
clarify controversies.
Outcome and follow up
After being discharged, patients were followed up according to
the protocol of each participating centre. Follow-up period
was calculated from surgery due to infection: debridement,
one-stage exchange or from the second stage in patients who
underwent a two-stage exchange. Among patients in remis-
sion, only those with at least 1 year of follow up were included
in the outcome analysis. Outcome was considered as failure
when inﬂammatory signs remained or re-appeared during or
after completing antibiotic treatment and/or the patient
needed an unplanned surgery to control the infection.
Death-related to infection and need for suppressive antimi-
crobial therapy were also considered as failures.
Statistical analysis
Variables were express as mean (SD), median (interquartile
range) or percentage. Continuous variables were compared by
Student’s t-test and the following variables were also catego-
rized: age (≤70 or >70 years), age of implant (≤30, 31–90 days,
91 days to 2 years or >2 years from arthroplasty), leucocyte
count (≤10 000 or >10 000 cells/mm3), C-reactive protein
(<5, 5–12 and >12 mg/dL) at the moment of admission for
infection. Categorical variables were compared by the
chi-square test or Fisher’s exact test when necessary. The
Kaplan–Meier survival method was used to estimate the
cumulative probability of remission. Variables signiﬁcantly
associated with failure in the univariable analysis were included
in a forward logistic regression model to identify independent
variables associated with failure. Statistical signiﬁcance was
deﬁned as a two-tailed p-value <0.05. The analysis was
performed using SPSS, version 20.0 (SPSS, Inc., Chicago, IL,
USA).
Results
Eighteen European centres from six different countries
participated in the study. A total of 203 patients with a PJI
due to Enterococcus sp. met the inclusion criteria. The mean
(SD) age of the cohort was 70.4 (13.6) years, and 75 were
male (40%). In 128 cases (63%) infection was on a hip
prosthesis, in 69 (34%) on a knee prosthesis and in six (3%) on
other joints (shoulder or elbow). The most frequent Entero-
coccus sp. was Enterococcus faecalis, which was isolated in 176
cases (89%) while Enterococcus faecium was found in 19 cases
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(9%) and both in three cases (2%). In ﬁve cases, the species was
not provided. In 107 (54%) patients the infection was
polymicrobial and the co-pathogens were coagulase-negative
staphylococci (37 cases, 19%), S. aureus (24 cases, 12%),
Escherichia coli (13 cases, 7%), Pseudomonas aeruginosa (14
cases, 7%), Enterobacter cloacae (four cases, 2%) and other
microorganisms (15 cases, 7%). The median (interquartile
range) duration of antibiotic treatment was 84 (53–147) days.
Debridement, antibiotics and implant retention was performed
in 102 (53%) cases, one-stage exchange in 29 (15%) and
two-stage exchange in 63 (32%). In nine cases the surgical
treatment was not provided.
Those patients in remission but with <1 year of follow up
were not considered for the outcome analysis. Therefore, 178
patients were included in the ﬁnal analysis. After a median
(interquartile range) post-surgical follow-up period of 722
(168–1529) days for patients with or without failure, 100
patients (56%) were considered to be in remission and 78
(44%) were considered as failures. Baseline characteristics,
surgical management and data according to the outcome are
shown in Table 1. Fig. 1 shows the cumulative probability of
remission at 2 years of follow up (failures identiﬁed later than
2 years are not included in the graph) according to the type of
Enterococcus sp. (log rank-test, p 0.002).
Infections diagnosed later than 2 years from arthroplasty
were associated with a higher remission rate (83%) than those
diagnosed ≤30 days (43%), between 31 and 90 days (44%) or
between 91 days and 2 years (63%) (p <0.001). Fig. 2 shows
the cumulative probability of remission at 2 years of follow up
(failures identiﬁed later than 2 years are not included in the
graph) according to the time from arthroplasty. Implant
removal was associated with a higher remission rate;
however, the analysis of surgical management (retention or
exchanging the implant) according to the age of implant at the
moment of infection diagnosis showed that removing the
implant was associated with a better prognosis only in those
patients with a very late (>2 years from arthroplasty) infection
(92% versus 50%, p 0.020; Table 2). In particular, one-stage
exchange had a higher success rate (77.3%) than two-stage
exchange (57.4%) or debridement (46.8%). The univariable
analysis of monomicrobial infections identiﬁed the same
variables associated with the outcome, and the results in
monomicrobial infections according to the age of implant and
surgical treatment were similar to those in polymicrobial
infections.
Regarding antibiotic treatment, the results for the antibiotic
administered for treating enterococci were analysed in infec-
tions that occurred ≤30 days from arthroplasty and those
diagnosed >30 days after arthroplasty. Only the administration
of rifampin, in combination with other antibiotics in early
infections was associated with a lower rate of failure than
other alternatives (Table 3).
A multivariate analysis using variables signiﬁcantly associated
with the outcome in the univariate analysis was performed.
Variables included were having or not having comorbidity, age
of prosthesis at the moment of infection diagnosis (>2 years
versus others), polymicrobial infection, type of Enterococcus sp.
(E. faecalis versus E. faecium), fever, and type of surgical
TABLE 1. Baseline characteristics according to the outcome
Characteristics
Remission
n = 100
Failure
n = 78 p value
Mean age (SD) years 71.3 (12.5) 68.1 (15.3) 0.13
Age > 70 years 67 (67.0) 45 (57.7) 0.20
Female 61 (61.0) 49 (62.8) 0.80
Comorbiditiesa
No comorbidities 48 (52.7) 19 (31.1) 0.009
Diabetes mellitus 19 (20.9) 16 (26.2) 0.44
Coronary disease 15 (23.4) 12 (22.6) 0.92
Chronic renal failure 10 (11.5) 12 (19.7) 0.17
Liver cirrhosis 4 (4.4) 8 (13.1) 0.06
Chronic obstructive pulmonary
diseases
7 (10.9) 4 (7.5) 0.75
Malignancy 12 (13.3) 5 (8.2) 0.33
Type of arthroplasty
Hip 57 (57.6) 55 (70.5) 0.17g
Knee 40 (40.4) 21 (26.9)
Other 3 (3.0) 2 (2.6)
Type of cementa
Non-cemented 21 (22.8) 13 (21.7) 0.38h
Cemented without ATB 69 (75.0) 43 (71.7)
Cemented with ATB 2 (2.2) 4 (6.7)
Median (IQR) age of
prosthesis in days
148 (32–904) 42 (15–124) 0.007
Age of implant at the moment of diagnosisb
<30 days 23 (23.2) 31 (40.3) <0.001i
30–90 days 19 (19.2) 24 (31.2)
91 days to 2 years 27 (27.3) 16 (20.8)
>2 years 30 (30.3) 6 (7.8)
Wound drainage 54 (60.7) 38 (61.3) 0.94
Fever 28 (28.9) 37 (48.7) 0.008
Mean (SD) leucocyte
count (cell/mm3)c
7717 (3375) 10 098 (4102) 0.001
Leucocyte count > 10 000
(cell/mm3)c
13 (21.3) 23 (44.2) 0.009
Mean (SD) C-reactive proteind 5.5 (5.1) 7.9 (6.4) 0.02
C-reactive protein
<5 mg/dL 46 (59.7) 23 (45.1) 0.06
5–12 mg/dL 21 (27.3) 16 (31.4)
>12 mg/dL 10 (13.0) 12 (23.5)
Antibiotic before surgery 31 (43.1) 25 (36.8) 0.45
Polymicrobial infection 48 (48) 51 (65) 0.04
Enterococcus sp.e
E. faecalis 89 (92.7) 64 (82.1) 0.04j
E. faecium 5 (5.2) 13 (16.7)
E. faecalis + E. faecium 2 (2.1) 1 (1.3)
Type of surgeryf
Debridement 44 (47.8) 50 (64.1) 0.17k
One-step exchange 17 (18.5) 5 (6.4)
Two-step exchange 31 (33.7) 23 (29.5)
Management of implant
Retention 44 (47.8) 50 (64.1) 0.03
Exchange (one or two stages) 48 (52.2) 28 (35.9)
Median (IQR) days of
ATB treatment
90 (60–180) 90 (45–148) 0.94
Abbreviations: ATB, antibiotic; IQR, interquartile range.
aThis variable was evaluated in 152 patients.
bThis variable was evaluated in 176 patients.
cThis variable was evaluated in 113 patients (61 in remission and 52 in failure
group).
dThis variable was evaluated in 128 patients.
eThe species was not provided in four cases.
fThis variable was evaluated in 170 patients.
gComparison between hip and knee prosthetic joint infection.
hComparison between non-cemented and cemented.
iComparison between >2 years and others.
jComparison between E. faecalis and E. faecium.
kComparison between one-stage and two-stage exchange.
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treatment (debridement versus exchange). Leucocyte count
and C-reactive protein were not included because the number
of patients with this information was limited. The ﬁnal model
identiﬁed, as risk factors for failure, the presence of any
comorbidity (OR 2.53, 95% CI 1.18–5.40, p 0.01), and fever
(OR 2.65, 95% CI 1.23–5.69, p 0.01). The only factor
associated with remission was infection diagnosed later than
2 years (OR 0.25, 95% CI 0.09–0.71, p 0.009).
Discussion
To our knowledge, this is the largest case series of PJI due to
Enterococcus sp. Prosthetic joint infections due to Enterococcus
sp. were diagnosed within the ﬁrst 2 years from arthroplasty in
79% of the cases and 48% of the patients had at least one
comorbidity (diabetes mellitus, coronary disease, chronic renal
failure, chronic obstructive pulmonary disease, malignancy or
liver cirrhosis). This microorganism has been classically
considered a difﬁcult-to-treat pathogen, therefore, one-stage
exchange is contraindicated and two-stage exchange is
recommended [12]. The previous largest series by El Helou
et al. [11] that reviewed the outcome of 50 enterococcal PJI
found a 2-year cumulative probability of success of 94% for
patients treated with two-stage exchange, 76% for those
treated with resection arthroplasty, and 80% for patients
treated with debridement and retention of the components,
results comparable to those reported for other microorgan-
isms [13]. However, they only included monomicrobial
FIG. 1. Cumulative probability of remission at 2 years follow up
according to the Enterococcus sp. (log-rank test p 0.002).
FIG. 2. Cumulative probability of remission at 2 years follow up
according to the time from arthroplasty (log-Rank test p 0.044).
TABLE 3. Outcome of different antibiotics used against
enterococci according to the age of implant at the time of
infection
Age of implant
at the moment
of infection Type of antibiotic
Remission
(%)
Failure
(%) p value
≤30 days Vancomycin 9 (36) 16 (64) 0.41
Ampicillin 6 (40) 9 (60) 1
Rifampina,b 12 (60) 8 (40) 0.04
Aminoglycosidea 3 (30) 7 (70) 0.49
Linezolid 4 (80) 1 (20) 0.15
Daptomycin 0 1 1
>30 days Vancomycin 37 (65) 20 (35) 0.60
Ampicillin 30 (67) 15 (33) 0.49
Rifampina 35 (58) 25 (42) 0.31
Aminoglycosidea 20 (54) 17 (46) 0.20
Linezolid 6 (46) 7 (54) 0.22
Daptomycin 3 (43) 4 (57) 0.42
aIn combination with one or more active antibiotics against enterococci.
bWith vancomycin in six cases, with vancomycin and aminoglycoside in one case,
with ampicillin and aminoglycoside in four cases, with linezolid in two cases and
with other antibiotic in seven cases.
TABLE 2. Outcome according to the type of surgical man-
agement and type of infection
Age of implant
at the moment
of infection Surgery Remission (%) Failure (%) p value
≤30 days Debridement 20 (41.6) 28 (58.4) 1
Exchange 2 (40) 3 (60)
31–90 days Debridement 12 (46.2) 14 (53.8) 0.58
Exchange 6 (37.5) 10 (62.5)
91 days to 2 years Debridement 8 (66.7) 4 (33.3) 0.72
Exchange 16 (57.1) 12 (42.9)
>2 years Debridement 4 (50.0) 4 (50.0) 0.02
Exchange 23 (92.0) 2 (8.0)
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infections and the ﬁrst ﬁnding of our multi-centric study was
that 54% of these infections were polymicrobial and they were
associated with a higher failure rate than monomicrobial
infections (52% versus 36%, p 0.042). Only late infections
treated with implant removal had a remission rate of 92%
(Table 2), similar to that described by El Helou et al. [11], but
other infections treated with either debridement or removal
of the implant had remission rates ≤50%. A potential
explanation is that late infections (>2 years from arthroplasty)
were less frequently polymicrobial than other infections
(>2 years from arthroplasty; 32% versus 59%). More recently,
Rasouli et al. [14] retrospectively reviewed 36 cases (39%
polymicrobial). Irrigation and debridement were performed in
11 patients as the initial treatment; however, eight of these 11
patients needed reoperation to control the infection. These
results are worse than those reported for S. aureus treated
with debridement [15,16] or implant removal [13] and support
the concept that the isolation of Enterococcus sp. is associated
with bad results, especially in PJI due to E. faecium (Fig. 1).
It is difﬁcult to know whether the poor results obtained in
enterococcal PJI are due to the affected population having
comorbidities, the high rate of polymicrobial infections, the
severity of the infection, the ability of enterococci to form
bioﬁlms or the lack of potent antibiotics against enterococci
[17,18]. Previous experience in a short case series of PJI due to
different microorganisms showed that enterococci as well as
methicillin-resistant S. aureus were independent predictors of
failure [9], suggesting that particular virulence or the lack of
effective antibiotics plays a role. Indeed, the analysis of the
main antibiotics used in early infections showed that those
patients receiving rifampin in combination with other active
antibiotic (vancomycin, ampicillin, aminoglycoside or linezolid)
had a higher remission rate than the alternatives without
rifampin (60%, p 0.04); however, larger studies are necessary
to conﬁrm this ﬁnding. Linezolid also had a high remission rate
(80%) but only ﬁve patients received this antibiotic and the
difference was not statistically signiﬁcant. Interestingly, linezo-
lid–rifampin combination has a good effect on E. faecalis
bioﬁlms in vitro [19]. The administration of aminoglycosides
was associated with a lower remission rate than other
alternatives, similar to what El Helou et al. [11] described
previously but in both cases there may be a selection bias
because more severe infections are candidates to receive an
aminoglycoside. In vitro and animal models have documented
synergy between ampicillin and ceftriaxone [20] and recently,
Euba et al. [21] described the efﬁcacy of this combination in
ten patients with orthopaedic infections with a remission rate
of 90%; however, only three were PJI. Other potential
combinations for the future could be a b-lactam plus dapto-
mycin [22,23] or fosfomycin [24].
There is increased interest in one-stage exchange for PJI
because it is associated with lower morbidity than two-stage
exchange [25]. The case series published by Rasouli et al. [14]
included six patients who underwent one-stage exchange and
the components were still in place at the latest follow up,
although one patient needed later irrigation and debridement.
The number of patients was low and we cannot rule out a
selection bias favouring one-stage exchange in the less severe
PJI.
The main limitation of our study is its retrospective nature
collecting information from different centres where the
decision for surgical approach or antibiotic treatment relied
on many different physicians. In addition, the number of
variables evaluated was limited and other factors (e.g. obesity,
previous surgeries, soft-tissue state) potentially inﬂuencing the
outcome were not recorded. However, this is the largest case
series from different countries and provides much information
about the characteristics and outcome of enterococcal PJI.
In conclusion, PJI due to Enterococcus sp. were diagnosed
within the ﬁrst 2 years from arthroplasty in >70% of the cases,
and almost 50% were associated with at least one comorbidity
and were frequently polymicrobial infections (54%). The global
failure rate was 44% and patients with comorbidities, fever and
diagnosed within the ﬁrst 2 years from arthroplasty had a poor
prognosis.
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